A Comprehensive Review of ANDA Submissions and Amendments Under GDUFA: FDA Guidelines for the Generic Drug Industry

This review provides an in-depth analysis of the Food and Drug Administration's (FDA) guidance document titled ANDA Submissions — Amendments to Abbreviated New Drug Applications (ANDAs) Under the Generic Drug User Fee Amendments (GDUFA), released in September 2024. The document serves as a comprehensive guide for the pharmaceutical industry, detailing the FDA's expectations regarding the classification, submission, and assessment of amendments to ANDAs and Prior Approval Supplements (PASs). The review discusses key elements of the guidance, including amendment categories (major, minor, and unsolicited), assessment timelines, the process for reclassification of amendments, and potential deficiencies in submissions. The guidance also addresses changes in classifications and assessment goals, deferred amendments, and best practices for ensuring timely FDA approval. This review aims to clarify the FDA’s current thinking on ANDA submissions under GDUFA and the practical implications for generic drug manufacturers seeking to comply with the established regulations.